HEMOCLOT QUANTI-V-L

HEMOCLOT Quanti. V-L is now CE Marked and 510(k) Approved

THE RIGHT SOLUTION FOR SOLVING THE LABOTARORY ISSUES FACED WHEN TESTING FACTOR V-LEIDEN



* Factor V mutated at position 506 (R506Q), also called Factor V-Leiden (V-L), induces a resistance to the action of Activated Protein C, and is associated with an increased thrombotic risk.

REGULATION OF BLOOD COAGULATION THROUGH THE PROTEIN C PATHWAY

Aniara | 6560 Gove Court, Mason, OH 45040 | Phone: 513-770-1991 | Toll Free: 866-783-3797 | FAX: 513-573-9241 | Web: www.aniara.com | Email: info@aniara.com

Form AH10
04-2007
Oct 2006/REF 026

A novel, specific and quantitative assay for measuring Factor V-leiden, with a single step clotting method

(HEMOCLOT Quanti-V-L–ACK065K)

PRINCIPLE

- Clotting method for measuring quantitatively Factor V-L (Factor V-Leiden) concentration in citrated plasma, by its resistance to the action of Activated Protein C (APC).
- The diluted plasma is mixed with purified clotting Factors, in presence of APC, in a constant and optimised concentration (R1: Prothrombin, Fibrinogen, Protein S and APC).The purified Factor Xa in presence of Phospholipids and calcium (R2) is then added. Clotting is initiated by addition of calcium (Ca2+) and the clotting times are then recorded. In presence of APC clotting time is inversely proportional to the concentration of factor V-L. There is an inverse linear relationship, on a linear (CT)-logarithmic (FVL) graph paper, between the factor V-L concentration and the corresponding clotting time.





R1: *Clotting mixture, containing human Fibrinogen, human Prothrombin, Protein S supplemented with human Activated Protein C and a heparin neutralizing substance, lyophilised.*

R2: *Purified Human Factor Xa, containing rabbit brain phospholipids (cephalin), lyophilised.*

Reagent not supplied :
CaCl2 0,025M





FACTOR V-LEIDEN CONCENTRATIONS

Normals (N = 30) :	< 5 %
Heterozygous (N = 8) :	35 to 60 %
Homozygous (N =2) :	> 100%
Dicoumarol therapy (non mutated) (N = 10)	< 5 %

- ➔ **One step clotting method** developed and designed using highly purified human coagulation proteins.
- ➔ **Fully quantitative assay** for the measurement of Factor V-Leiden (V-L) on citrated plasma.
- ➔ Performed using **only one clotting test**.
- ➔ **Excellent discrimination** (clotting time and Factor V-L concentrations) between normal, heterozygous and homozygous patients (for the R506Q mutation).
- ➔ Highly robust assay offering **excellent intra-** (<3%) **and inter-assay** (<5%) reproducibilities.
- ➔ **No interference** of heparin or dicoumarol therapy.
- ➔ **Easy to perform, cost effective and reliable assay, fully automatable on laboratory instruments.**

Aniara 6560 Gove Court Mason, OH 45040
Phone: 513-770-1991 **Toll Free**: 866-783-3797 **FAX**: 513-573-9241
Web: www.aniara.com **Email**: info@aniara.com